Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNYTE-3: Vusolimogene oderparepvec + nivolumab vs physician’s choice in advanced melanoma after PD-1 and CTLA-4
2023-508612-29-00Phase 3Authorised
- Sponsor
- Replimune Group, Inc.
- Start
- Jul 2025
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of vusolimogene oderparepvec in cutaneous melanoma (CM) (2 arms), sponsored by Replimune Group, Inc. Primary endpoint: Overall survival. Planned start Jul 2025; status: authorised.
02
Drugs
vusolimogene oderparepvec
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2023-508612-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508612-29-00.